The bill S. 5383 proposes to classify two substances, MGM-15 and MGM-16, as Schedule I controlled substances under the Controlled Substances Act. Additionally, it seeks to categorize synthetic 7-hydroxymitragynine and Mitragynine Pseudoindoxyl as Schedule I controlled substances as well. This classification indicates that these substances are considered to have a high potential for abuse and no accepted medical use.
Supporters of the bill argue that scheduling these substances is necessary to protect public health and safety. They highlight concerns about the potential for abuse and addiction associated with synthetic derivatives of kratom and other related substances, emphasizing the need for regulatory oversight.
Critics of the bill contend that scheduling these substances could hinder research and limit access to potential therapeutic benefits. They argue that the decision is driven by fear rather than scientific evidence, and express concerns about the implications for individuals who use these substances for pain management or other health issues.
The donor data provided consists entirely of individual contributions from employees of Applied Materials, Inc., a company not directly related to the substances mentioned in the bill. There is no evidence of PAC donations or direct conflict of interest with the bill's subject matter.
